Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer.
Angela ChouDanielle FroioAdnan M NagrialAshleigh ParkinKendelle J MurphyVenessa T ChinDalia WohlAngela SteinmannRhys StarkAlison DruryStacey N WaltersClaire VenninAndrew BurgessMark PineseLorraine A ChantrillMark J CowleyTimothy J Molloynull nullNicola WaddellAmber JohnsSean M GrimmondDavid K ChangAndrew V BiankinOwen J SansomJennifer P MortonShane T GreyThomas R CoxJohn TurchiniJaswinder SamraStephen J ClarkePaul TimpsonAnthony J GillMarina PajicPublished in: Gut (2017)
This study demonstrates the promise of CDK4 inhibition in PDA over standard therapy when applied in a molecular subtype-specific context.